# Moat Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moat-biotechnology

- Industry: Biotechnology
- Headquarters: Oklahoma City, US
- Latest round: Series C (Jun 30, 2022)
- Investors on record: 1

## About

Based in Oklahoma, US, and founded in 2022, Moat Biotechnology is a biopharmaceutical company focused on the development of novel intranasal and oral vaccines. As of 2023, the company is headed by its CEO Dr. Scott Rollins, who also co-founded the firm. In June 2023, the firm raised USD 6.5 million in venture funding led by investor Cortado Ventures, with participation from investor Boyd Street Ventures.

The company develops intranasal and oral vaccines based on the SC-AdVax platform which is licensed from the Mayo Clinic. The firm offerings help in mucosal and systemic immunity for the treatment of viruses and infectious diseases.

The company plans to use the June 2023 funding to expand its ongoing Phase 1 clinical trial of an intranasal boost for COVID-19 and initiate the development of 2nd and 3rd SC-AdVax vaccines for additional mucosal pathogens.

## Funding rounds

- Series C, Jun 30, 2022 — Cortado Ventures
- Series C, Jun 15, 2020 — Cortado Ventures

## Investors

- Cortado Ventures (https://capitalatlas.ai/funds/cortado-ventures) — Series C